NEWS RELEASE - AUGUST 2, 2022
ELO is pleased to announce that Sir Andrew Pollard, Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford, will participate in the ELO Leadership Programme.
Sir Andrew was the chief investigator for the clinical trials of the Oxford-AstraZeneca COVID-19 vaccine in 2020, which led to the authorisation of the vaccine for use in more than 175 countries with over 2.5 billion doses distributed by the end of 2021.
Dr. Richard (Rick) J. Goossen, Chairman, ELO, noted: "The story of the Oxford-AstraZeneca vaccine is one of innovation and successful commercialization, with massive impact. It is one of the world's most important entrepreneurial initiatives of the past few years."
“Sir Andrew’s involvement adds to a world-class roster of presenters from the University of Oxford, supplemented by instructors from Europe, North America, and Asia, which further solidifies ELO’s vision to deliver the premier executive education experience for Christian marketplace and entrepreneurial leaders.”
Dr. Goossen will facilitate a Q & A session with Sir Andrew and allow the cohort to get a unique perspective on the development of the vaccine and the various challenges and thrills along the way.
Sir Andrew’s research includes the design, development and clinical evaluation of vaccines in the UK, Asia, Africa, and Latin America, including those for COVID-19, typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, pertussis, influenza, rabies, coronavirus and Ebola, and leads studies using a human challenge model of paratyphoid and typhoid.
He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health, especially during the pandemic.
Dr. Goossen previously posted four blog posts on the story of the Oxford-AstraZeneca vaccine:
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Go from Idea to Opportunity? (Part I)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Solve a Global Problem? (Part II)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: What's The Deal? (Part III)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Execute? (Part IV)